Summary
Global Markets Direct’s, ‘Peanut Allergy - Pipeline Review, H1 2016’, provides an overview of the Peanut Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peanut Allergy
- The report reviews pipeline therapeutics for Peanut Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peanut Allergy therapeutics and enlists all their major and minor projects
- The report assesses Peanut Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peanut Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peanut Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aimmune Therapeutics, Inc.
AnaptysBio, Inc.
Array BioPharma Inc.
ASIT biotech s.a.
BioLingus AG
DBV Technologies S.A.
HAL Allergy BV
Immunomic Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peanut Allergy Overview 9
Therapeutics Development 10
Pipeline Products for Peanut Allergy - Overview 10
Pipeline Products for Peanut Allergy - Comparative Analysis 11
Peanut Allergy - Therapeutics under Development by Companies 12
Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 13
Peanut Allergy - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Peanut Allergy - Products under Development by Companies 18
Peanut Allergy - Products under Investigation by Universities/Institutes 19
Peanut Allergy - Companies Involved in Therapeutics Development 20
Aimmune Therapeutics, Inc. 20
AnaptysBio, Inc. 21
Array BioPharma Inc. 22
ASIT biotech s.a. 23
BioLingus AG 24
DBV Technologies S.A. 25
HAL Allergy BV 26
Immunomic Therapeutics, Inc. 27
Peanut Allergy - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
aldesleukin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Allergen for Peanut Allergy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Allergen for Peanut Allergy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Allergen for Peanut Allergy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Allergen for Peanut Allergy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ANB-020 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AR-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AR-460770 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ASP-0892 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DBV-712 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
INT-301 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PER-1080 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pnut-ASIT - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Recombinant Protein for Peanut Allergy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SCV-209 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Vaccine for Peanut Allergy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Vaccine for Peanut Allergy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
VTC-064 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Peanut Allergy - Recent Pipeline Updates 60
Peanut Allergy - Dormant Projects 68
Peanut Allergy - Discontinued Products 69
Peanut Allergy - Product Development Milestones 70
Featured News & Press Releases 70
Apr 11, 2016: Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101 70
Mar 06, 2016: Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance 72
Mar 06, 2016: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance 74
Mar 04, 2016: DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy 75
Mar 01, 2016: Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy 76
Feb 25, 2016: DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology Supporting Safety and Tolerability of Viaskin Peanut 77
Feb 10, 2016: DBV Technologies to Present New Data on Viaskin Peanut Allergy at the 2016 AAAAI Annual Meeting 78
Jan 11, 2016: Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy 81
Dec 07, 2015: DBV Technologies Announces Initiation of Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children 82
Nov 11, 2015: Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List of Tables
Number of Products under Development for Peanut Allergy, H1 2016 10
Number of Products under Development for Peanut Allergy - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Peanut Allergy - Pipeline by Aimmune Therapeutics, Inc., H1 2016 20
Peanut Allergy - Pipeline by AnaptysBio, Inc., H1 2016 21
Peanut Allergy - Pipeline by Array BioPharma Inc., H1 2016 22
Peanut Allergy - Pipeline by ASIT biotech s.a., H1 2016 23
Peanut Allergy - Pipeline by BioLingus AG, H1 2016 24
Peanut Allergy - Pipeline by DBV Technologies S.A., H1 2016 25
Peanut Allergy - Pipeline by HAL Allergy BV, H1 2016 26
Peanut Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Peanut Allergy Therapeutics - Recent Pipeline Updates, H1 2016 60
Peanut Allergy - Dormant Projects, H1 2016 68
Peanut Allergy - Discontinued Products, H1 2016 69
List of Figures
Number of Products under Development for Peanut Allergy, H1 2016 10
Number of Products under Development for Peanut Allergy - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Targets, H1 2016 29
Number of Products by Stage and Targets, H1 2016 29
Number of Products by Mechanism of Actions, H1 2016 31
Number of Products by Stage and Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35
